Weekly Industry News – Pharma & Healthcare

Pharma & Healthcare – the latest on regulatory costs, FDI proposals and more.  

Regulatory costs will rise, fines will increase, expert warns by Dan Shanton Published on Outsourcing-Pharma

Economic uncertainty and a bleak fiscal outlook will lead to over-regulation and increased fines in the clinical trial industry, according to an economic expert at PCT… [ Read More ]

Cabinet defers consideration of pharma, housing FDI proposals by PTI Published on Economics Times

The Cabinet today deferred the consideration of proposals to relax foreign direct investment norms in the housing sector and to reduce the FDI cap to 49 per cent in critical areas of the pharma segment.  The strategy for the WTO ministerial conference in Bali next month was also not discussed… [  Read More  ]

Cabinet may restrict pharma FDI as drug costs rise by  Sandeep Phukan Published on profit.ndtv.com 

The UPA government may be trying its best to attract foreign direct investment, or FDI, but there is, at least, one sector where the government wants to bring it down. The Cabinet will decide on FDI limit in existing pharmaceutical companies producing critical medicines. The Department Industrial Policy & Promotion (DIPP) of Commerce Ministry wants to bring down FDI limit in existing pharma companies to 49 per cent from the current norm of 100 per cent… [ Read More  ]

 

Live Industry News

 Follow @ACI_Pharma & @ACI_Health  Join ACI Pharmaceuticals/Biotech/Life Sciences Experts  Group Join ACI Healthcare: Legal, Regulatory, and Compliance Experts Group  

Related Events

          For a complete list of all Pharma upcoming events: Click Here For a complete list of all Healthcare upcoming events: Click Here For a list of past Pharma conference proceedings: Click Here For a list of past Healthcare conference proceedings: Click Here  

     

Tags: Weekly Industry News